Opinion|Videos|October 18, 2024
Improving Access to Lupus Nephritis Treatment: Strategies and Resources
Key Takeaways
- Financial constraints and limited healthcare access are significant barriers to timely lupus nephritis treatment, affecting patient outcomes.
- Patient assistance programs, educational initiatives, and support groups are crucial resources for facilitating access to lupus nephritis care.
Panelists discuss the challenges patients face in accessing lupus nephritis treatment and the resources available to support timely access, including how payers are facilitating care.
Advertisement
Episodes in this series
- What challenges or barriers do patients face when accessing lupus nephritis (LN) treatment, and what resources are available to support timely access to treatment?
- How are payers supporting timely access to care in LN?
Advertisement
Related to this article
The FDA approved talazoparib plus enzalutamide for HRR-mutated metastatic hormone-sensitive prostate cancer after TALAPRO-3 cut progression risk by 52%.
Unclear ownership often leaves survivors without support, and coverage of social and psychological services could close the gap, says Bhatnagar.
Adults with moderately to severely active Crohn disease can now start risankizumab with an on-body injector at home.
This system-level initiative significantly increased guideline-concordant venous thromboembolism prophylaxis rates in hospitalized patients through coordinated education, clinical decision tools, audit-feedback, and pharmacist integration.
For all the advances in breast cancer, there remains unmet need for patients whose cancer progresses after treatment with antibody-drug conjugates (ADCs). In the final week of Breast Cancer Awareness Month, AJMC® looks at an investigational vaccine approach that could come after ADCs, offering patients a low-toxicity regimen.
Nevena Vicic, MSc, discusses first real-world data showing mRNA-1283 protected adults 65 and older from COVID-19 hospitalization in 2025-2026.
He sees progress in Richter combination therapies, explains how patient goals shape CLL treatment, and reflects on mentoring trainees.
CEO Susan Cantrell previews AMCP Nexus 2026, discussing AI, drug pricing, emerging therapies, and a decade of change in managed care pharmacy.
Advertisement
Advertisement
Trending on AJMC
1
IDWeek Studies Tie RSV, Flu, and COVID-19 to Harm After Acute Illness
2
Preparing for Hepatitis B Functional Cure: Jordan Feld, MD, MPH
3
Povetacicept Cuts Proteinuria by 52% in IgA Nephropathy at Week 36
4
Nephrologists Weigh Wins, Losses From 5 Years of Value-Based Kidney Care
5